Market Overview

Mylan Launches Generic Version of Qualaquin Caps

Share:
Related MYL
Benzinga's M&A Chatter for Wednesday July 29, 2015
RBC Says Stay Away From Mylan, Perrigo; Go Long Teva, Allergan
Should You Buy Evolving Trends in Medical Devices? - Industry Outlook (Zacks)

Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quinine Sulfate Capsules USP, 324 mg. This product is the generic version of Mutual Pharmaceutical Company, Inc.'s Qualaquin^® Capsules, and is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria.(1)

Quinine Sulfate Capsules USP, 324 mg, had U.S. sales of approximately $31.9 million for the 12 months ending Sept. 30, 2012, according to IMS Health. Mylan has begun shipping this product.

Posted-In: News

 

Related Articles (MYL)

Get Benzinga's Newsletters